ReviewClinical and experimental medicine2023
CXCL6: A potential therapeutic target for inflammation and cancer.
Review in Clinical and experimental medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 28 citations in OpenAlex.
- Spatial characterization of interface dermatitis in cutaneous lupus reveals novel chemokine axis-mediated recruitment of leukocytes that drive disease.Scientific reports · 2026Article
- Article
- Clinical and molecular correlates of digitally quantified anthracosis in lung tissue slides: utility of an automated quantitative workflow.The journal of pathology. Clinical research · 2026Article
- Impact of older donor age in kidney transplants in a biopsy-based observational study.JCI insight · 2026Observational
- CXCL8 producing macrophages shape gastric cancer outcomes.Discover oncology · 2026Article
- Cytokines and cancer-associated fibroblasts.Journal of hematology & oncology · 2026Review
- Comparative profiling of extracellular vesicles and miRNA cargo from in vivo- and in vitro-derived bovine embryos during blastulation and hatching.Journal of animal science and biotechnology · 2026Article
- Uncovering potentially targetable genes in liver fibrosis via bioinformatics and experimental validation.Scientific reports · 2026Article
- C-X-C motif chemokine ligand 13 and the C-X-C motif chemokine receptor 5-c-Jun N-terminal kinase-nuclear factor kappa B-matrix metalloproteinase 9 axis in oral squamous cell carcinoma metastasis.Journal of dental sciences · 2026Article
- Circulating inflammatory proteins as pathogenic mediators and potential therapeutic targets in myasthenia gravis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Article
- Bidirectional Interaction Between PGEProteomes · 2025Article
- A Comprehensive Mass Spectrometry-Based Proteomic Dataset of Human Spermatozoa.Scientific data · 2025Article
- Angiogenesis-Related Genes Predict Outcomes and Immune Traits in Skin Melanoma.International journal of molecular sciences · 2025Article
- Evidence for a JAK2/STAT3 proinflammatory and vasculogenic mimicry interrelated molecular signature in adipocyte-derived mesenchymal stromal/stem cells.Cell communication and signaling : CCS · 2025Article
- Inflammatory diseases and risk of lung cancer among individuals who have never smoked.Nature communications · 2025Article
- A cross-sectional study of the role of epithelial cell injury in kidney transplant outcomes.JCI insight · 2025Observational
- New insights into tRNA-derived small RNAs in human digestive diseases.Molecular biology reports · 2025Review
- Shared immune-inflammatory mechanisms between ulcerative colitis and periodontitis: a multi-omics analysis.Frontiers in immunology · 2025Article
- Causal effects of circulating inflammatory proteins on knee and hip osteoarthritis: A two sample Mendelian randomization study.Clinical rheumatology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Chemokines were originally defined as cytokines that affect the movement of immune cells. In recent years, due to the increasing importance of immune cells in the tumor microenvironment (TME), the role of chemokines has changed from a single "chemotactic agent" to a key factor that can regulate TME and affect the tumor phenotype. CXCL6, also known as granulocyte chemoattractant protein-2 (GCP-2), can recruit neutrophils to complete non-specific immunity in the process of inflammation. Cancer-related genes and interleukin family can promote the abnormal secretion of CXCL6, which promotes tumor growth, metastasis, epithelial mesenchymal transformation (EMT) and angiogenesis in the TME. CXCL6 also has a role in promoting fibrosis and tissue damage repair. In this review, we focus on the regulatory network affecting CXCL6 expression, its role in the progress of inflammation and how it affects tumorigenesis and progression based on the TME, in an attempt to provide a potential target for the treatment of diseases such as inflammation and cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.